David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 23.09% |
| 2 | Technology | 17.04% |
| 3 | Healthcare | 13.44% |
| 4 | Consumer Discretionary | 13.38% |
| 5 | Financials | 7.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2201
Criteo S.A.
CRTO
$848M
| $1.74M | ﹤0.01% |
86,976
-35,093
| -29% | -$894K |
|
2202
PUT
C.H. Robinson
CHRW
$17.7B
| $1.74M | ﹤0.01% |
20,000
| – | – |
|
2203
Angi Inc
ANGI
$186M
| $1.74M | ﹤0.01% |
11,247
-8,023
| -42% | -$1.3M |
|
2204
UNIFI
UFI
$139M
| $1.74M | ﹤0.01% |
89,744
+53,681
| +149% | +$1.17M |
|
|
CLVS
2205
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
| $1.74M | ﹤0.01% |
70,000
-152,400
| -69% | -$3.82M |
|
|
GRMN
2206
CALL
Garmin
GRMN
$55.9B
| $1.74M | ﹤0.01% |
+20,100
| New | +$1.51M |
|
2207
Hanover Insurance
THG
$7.94B
| $1.74M | ﹤0.01% |
15,197
-17,023
| -53% | -$1.96M |
|
|
SWIR
2208
DELISTED
Sierra Wireless
SWIR
| $1.74M | ﹤0.01% |
140,255
+104,766
| +295% | +$1.44M |
|
2209
CALL
NetApp
NTAP
$37.2B
| $1.73M | ﹤0.01% |
25,000
| – | – |
|
2210
PUT
Fluor
FLR
$7.21B
| $1.73M | ﹤0.01% |
47,100
+35,200
| +296% | +$1.29M |
|
2211
LGI Homes
LGIH
$1.33B
| $1.73M | ﹤0.01% |
+28,745
| New | +$1.66M |
|
2212
Sempra
SRE
$55.4B
| $1.73M | ﹤0.01% |
27,518
-87,620
| -76% | -$5.16M |
|
|
VRAY
2213
DELISTED
ViewRay, Inc.
VRAY
| $1.73M | ﹤0.01% |
+234,359
| New | +$1.81M |
|
2214
CALL
Madrigal Pharmaceuticals
MDGL
$12.5B
| $1.73M | ﹤0.01% |
13,800
| – | – |
|
2215
Duluth Holdings
DLTH
$143M
| $1.73M | ﹤0.01% |
72,504
+19,035
| +36% | +$452K |
|
|
CMRX
2216
DELISTED
Chimerix, Inc.
CMRX
| $1.73M | ﹤0.01% |
822,695
+163,401
| +25% | +$372K |
|
|
WWE
2217
DELISTED
World Wrestling Entertainment
WWE
| $1.73M | ﹤0.01% |
19,903
+16,103
| +424% | +$1.36M |
|
|
CYBR
2218
PUT
DELISTED
CyberArk
CYBR
| $1.73M | ﹤0.01% |
+14,500
| New | +$1.39M |
|
|
CSOD
2219
CALL
DELISTED
Cornerstone OnDemand, Inc.
CSOD
| $1.73M | ﹤0.01% |
31,500
-10,000
| -24% | -$553K |
|
2220
CALL
Zimmer Biomet
ZBH
$19.1B
| $1.72M | ﹤0.01% |
+13,905
| New | +$1.58M |
|
2221
Clean Energy Fuels
CLNE
$351M
| $1.72M | ﹤0.01% |
557,499
+101,486
| +22% | +$226K |
|
2222
Elevance Health
ELV
$86.9B
| $1.72M | ﹤0.01% |
5,995
-15,605
| -72% | -$4.51M |
|
2223
Kiniksa Pharmaceuticals
KNSA
$6.29B
| $1.72M | ﹤0.01% |
95,256
+85,714
| +898% | +$1.66M |
|
2224
Aflac
AFL
$58.6B
| $1.72M | ﹤0.01% |
34,341
-22,494
| -40% | -$1.08M |
|
2225
CALL
Wolfspeed
WOLF
$1.4B
| $1.72M | ﹤0.01% |
30,000
-2,400
| -7% | -$123K |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $2.66B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 23% of assets, down from 26% a quarter earlier, followed by Technology and Healthcare.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.